No profile data available.
Arvinas, Inc. (ARVN) is a healthcare company in the additional cancer treatment drugs industry, based in New Haven, United States, with about 246 full-time employees.
It reported revenue of $262.60 million for fiscal year 2025, down 0.3% from fiscal year 2024, and net income of -$80.80 million. Its market capitalization was $499.55 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas reported $262.60 million in revenue for fiscal year 2025, down 0.3% from $263.40 million in fiscal year 2024.
$499.55 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include CytomX Therapeutics, Inc. (CTMX), Crescent Biopharma, Inc. (CBIO), Allogene Therapeutics, Inc. (ALLO), Autolus Therapeutics plc (AUTL).